Henry Schein Q2FY26 Results: Non-GAAP EPS up 15.5%, guidance raised
- Non-GAAP EPS rose 15.5% to $1.27, outpacing 6.7% sales growth
- Full-year FY26 sales guidance raised to 4.5%-5.5%, EPS to $5.29-$5.39
- U.S. dental merchandise sales grew 8.3%, international dental merchandise up 11.1%
- High-margin businesses now contribute nearly 50% of total operating income
*this image is generated using AI for illustrative purposes only.
Henry Schein (NASDAQ: HSIC) reported strong second-quarter fiscal 2026 results on August 4, 2026, with non-GAAP earnings per share rising 15.5% to $1.27. Global sales increased 6.7% to $3.5 billion, driven by internal local currency growth of 4.6% and favorable foreign exchange impacts.
The healthcare products and services provider raised its full-year FY26 guidance, now expecting total sales growth of 4.5% to 5.5% and non-GAAP diluted EPS between $5.29 and $5.39. This revision reflects sustained sales momentum and early benefits from value creation initiatives, which target at least $200 million in operating income improvements over the next few years.
Segment Performance
The company’s three primary reporting segments all contributed to the quarter’s growth. The Global Distribution and Value-Added Services Group saw sales grow 6.6%, while the Global Specialty Products Group expanded 8.7%. The Global Technology Group posted the highest growth rate at 8.2%.
| Metric | Q2FY26 | Q2FY25 | Change |
|---|---|---|---|
| Total Sales | $3.5 billion | N/A | +6.7% |
| Internal Local Currency Sales Growth | 4.6% | N/A | N/A |
| Non-GAAP Operating Income Growth | 10.5% | N/A | N/A |
| Non-GAAP EPS | $1.27 | $1.10 | +15.5% |
| Adjusted EBITDA | $288 million | $256 million | +12.7% |
Key drivers included U.S. dental merchandise sales, which grew 8.3%, and international dental merchandise sales, which rose 11.1%. The technology segment benefited from a shift toward cloud-based solutions, with nearly 13,000 customers subscribing to Dentrix Ascend and Dentally platforms.
Strategic Initiatives and Guidance
Management highlighted progress in simplifying operations and deepening customer relationships. A key focus is the expansion of Henry Schein One’s AI-enabled capabilities, which are driving higher monthly revenue per customer. Average monthly revenue for Dentrix Ascend customers is approximately $800, compared to roughly $500 for the broader Henry Schein One base.
The company repurchased approximately 2.6 million shares for $200 million during the quarter. Operating cash flow stood at $242 million, supporting the company’s capital deployment strategy. For the remainder of FY26, management expects fourth-quarter earnings growth to exceed third-quarter growth due to increasing benefits from value creation projects.
What the Numbers Show
A divergence exists between top-line acceleration and bottom-line leverage. While total sales grew 6.7%, non-GAAP EPS grew 15.5%, indicating significant margin expansion driven by operational efficiency rather than volume alone. This is supported by the disclosure that high-growth, high-margin businesses now represent almost 50% of total operating income, a structural shift that amplifies profitability relative to revenue growth.
How will the shift toward cloud-based solutions and AI-enabled capabilities impact Henry Schein's long-term customer retention rates and competitive moat against emerging digital health platforms?
To what extent can the company sustain its current pace of margin expansion as it targets $200 million in operating income improvements, particularly if foreign exchange tailwinds reverse in future quarters?
What are the potential regulatory or reimbursement implications for healthcare providers adopting Henry Schein's AI-driven technology, and how might this affect adoption speed among smaller practices?
18
Access Market Heat-map & Insights 
Create, Save & Share your Screener 
Use 200+ Screening Filters 
